Alternative Data for Amphastar P
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 87 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 8 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,129 | Sign up | Sign up | Sign up |
| X Mentions | 16 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
| Price | $20.27 |
| Target Price | Sign up |
| Volume | 496,700 |
| Market Cap | $922M |
| Year Range | $19.83 - $30.81 |
| Dividend Yield | 0% |
| PE Ratio | 8.77 |
| Analyst Rating | 67% buy |
| Industry | Biotechnology |
In the news
 |
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14 - SeekingAlpha |
Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' LabelFebruary 27 - SeekingAlpha |
|
 |
Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market SessionFebruary 26 - Benzinga |
 |
12 Health Care Stocks Moving In Friday's Pre-Market SessionFebruary 26 - Benzinga |
 |
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving PremarketFebruary 26 - Benzinga |
 |
Wondering what's happening in today's after-hours session?February 26 - ChartMill |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 192M | 93M | 99M | 17M | 42M | 0.930 |
| Q2 '25 | 174M | 88M | 86M | 31M | 62M | 0.850 |
| Q1 '25 | 171M | 85M | 85M | 25M | 52M | 0.740 |
| Q4 '24 | 187M | 100M | 87M | 38M | 65M | 0.920 |
| Q3 '24 | 189M | 87M | 102M | 40M | 69M | 0.960 |
Insider Transactions View All
| Zhou Rong filed to sell 138,043 shares at $26.2. December 18 '25 |
| Petersen Floyd F. filed to sell 71,368 shares at $25.9. December 15 '25 |
| Petersen Floyd F. filed to sell 73,794 shares at $25.7. December 15 '25 |
| PRINS RICHARD K filed to sell 35,183 shares at $27.1. November 25 '25 |
| Petersen Floyd F. filed to sell 75,531 shares at $26.5. November 17 '25 |
Similar companies
Read more about Amphastar P (AMPH) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Amphastar P
The Market Cap of Amphastar P is $922M.
As of today, Amphastar P's PE (Price to Earnings) ratio is 8.77.
Currently, the price of one share of Amphastar P stock is $20.27.
The AMPH stock price chart above provides a comprehensive visual representation of Amphastar P's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amphastar P shares. Our platform offers an up-to-date AMPH stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Amphastar P (AMPH) does not offer dividends to its shareholders. Investors interested in Amphastar P should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Amphastar P are Anavex Life Sciences, BridgeBio Pharma, Crispr Therapeutics, Editas Medicine, and Amarin.
